GB201020607D0 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- GB201020607D0 GB201020607D0 GBGB1020607.6A GB201020607A GB201020607D0 GB 201020607 D0 GB201020607 D0 GB 201020607D0 GB 201020607 A GB201020607 A GB 201020607A GB 201020607 D0 GB201020607 D0 GB 201020607D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (37)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1020607.6A GB201020607D0 (en) | 2010-12-06 | 2010-12-06 | Novel compounds |
SG2013035357A SG190203A1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
BR112013013914-5A BR112013013914B1 (en) | 2010-12-06 | 2011-12-06 | HIDANTOIN DERIVED COMPOUNDS USEFUL AS KV3 INHIBITORS, USES OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITION INCLUDING THEM |
AU2011340258A AU2011340258C1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as Kv3 inhibitors |
CA2817205A CA2817205C (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
MX2013006343A MX338489B (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors. |
KR1020137017537A KR101862375B1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
EP11805571.4A EP2649066B1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
PL11805571T PL2649066T3 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
PCT/GB2011/052414 WO2012076877A1 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
JP2013542606A JP5913357B2 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as KV3 inhibitors |
EA201390609A EA023768B1 (en) | 2010-12-06 | 2011-12-06 | HYDANTOIN DERIVATIVES USEFUL AS INHIBITORS OF Kv3 CHANNELS |
US13/991,486 US9346790B2 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as Kv3 inhibitors |
DK11805571.4T DK2649066T3 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives using as KV3 inhibitors. |
CN201180058712.3A CN103328467B (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as KV3 inhibitors |
ES11805571.4T ES2560304T3 (en) | 2010-12-06 | 2011-12-06 | Hydantoin derivatives useful as Kv3 inhibitors |
US14/361,510 US9133175B2 (en) | 2010-12-06 | 2012-12-06 | Compounds |
EA201490922A EA027532B1 (en) | 2010-12-06 | 2012-12-06 | HYDANTOIN DERIVATIVES USEFUL AS INHIBITORS OF Kv3 CHANNELS |
BR112014013400-6A BR112014013400B1 (en) | 2010-12-06 | 2012-12-06 | Compounds derived from hydantoin useful as inhibitors of kv3 and their uses in the prophylaxis or treatment of hearing disorders and schizophrenia or in the treatment of fragile X syndrome |
SG11201402529RA SG11201402529RA (en) | 2010-12-06 | 2012-12-06 | Hydantoin derivatives useful as kv3 inhibitors |
IL226256A IL226256A0 (en) | 2010-12-06 | 2013-05-09 | Hydantoin derivatives useful as kv3 inhibitors |
HK14103468.1A HK1190395A1 (en) | 2010-12-06 | 2014-04-10 | Hydantoin derivatives useful as kv3 inhibitors kv3 |
ZA2014/03529A ZA201403529B (en) | 2010-12-06 | 2014-05-15 | Hydantoin derivatives useful as kv3 inhibitors |
US14/816,476 US9422272B2 (en) | 2010-12-06 | 2015-08-03 | Compounds |
JP2016023519A JP6118927B2 (en) | 2010-12-06 | 2016-02-10 | Hydantoin derivatives useful as KV3 inhibitors |
US15/093,004 US20160251340A1 (en) | 2010-12-06 | 2016-04-07 | Hydantoin derivatives useful as kv3 inhibitors |
US15/206,465 US9833452B2 (en) | 2010-12-06 | 2016-07-11 | Compounds |
US15/621,400 US10265316B2 (en) | 2010-12-06 | 2017-06-13 | Hydantoin derivatives useful as Kv3 inhibitors |
IL253104A IL253104A0 (en) | 2010-12-06 | 2017-06-22 | Hydantoin derivatives useful as kv3 inhibitors |
IL253102A IL253102B (en) | 2010-12-06 | 2017-06-22 | Hydantoin derivatives useful as kv3 inhibitors |
US15/730,559 US10098881B2 (en) | 2010-12-06 | 2017-10-11 | Compounds |
US16/125,148 US10555945B2 (en) | 2010-12-06 | 2018-09-07 | Compounds |
US16/285,996 US20190192516A1 (en) | 2010-12-06 | 2019-02-26 | Hydantoin derivatives useful as kv3 inhibitors |
US16/725,709 US10835534B2 (en) | 2010-12-06 | 2019-12-23 | Compounds |
US16/985,160 US11197859B2 (en) | 2010-12-06 | 2020-08-04 | Hydantoin derivatives useful as Kv3 inhibitors |
US17/030,268 US11541052B2 (en) | 2010-12-06 | 2020-09-23 | Compounds |
US17/517,620 US11583527B2 (en) | 2010-12-06 | 2021-11-02 | Hydantoin derivatives useful as Kv3 inhibitors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1020607.6A GB201020607D0 (en) | 2010-12-06 | 2010-12-06 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201020607D0 true GB201020607D0 (en) | 2011-01-19 |
Family
ID=43531502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1020607.6A Ceased GB201020607D0 (en) | 2010-12-06 | 2010-12-06 | Novel compounds |
Country Status (2)
Country | Link |
---|---|
BR (1) | BR112014013400B1 (en) |
GB (1) | GB201020607D0 (en) |
-
2010
- 2010-12-06 GB GBGB1020607.6A patent/GB201020607D0/en not_active Ceased
-
2012
- 2012-12-06 BR BR112014013400-6A patent/BR112014013400B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BR112014013400A2 (en) | 2017-06-13 |
BR112014013400B1 (en) | 2022-04-12 |
BR112014013400A8 (en) | 2021-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201005589D0 (en) | Novel compounds | |
GB201007203D0 (en) | Novel compounds | |
EP2590647A4 (en) | Pro-neurogenic compounds | |
GB201012686D0 (en) | Novel compounds | |
GB201007791D0 (en) | Novel compounds | |
GB201021314D0 (en) | Novel compounds | |
GB201021311D0 (en) | Novel compounds | |
GB201021310D0 (en) | Novel compounds | |
GB201020909D0 (en) | Novel compounds | |
GB201020622D0 (en) | Novel compounds | |
GB201020607D0 (en) | Novel compounds | |
GB201019547D0 (en) | Novel compounds | |
GB201019576D0 (en) | Novel compounds | |
GB201019480D0 (en) | Novel compounds | |
GB201019575D0 (en) | Novel compounds | |
GB201014232D0 (en) | Novel compounds | |
GB201014231D0 (en) | Novel compounds | |
GB201014230D0 (en) | Novel compounds | |
GB201012924D0 (en) | Novel compounds | |
GB201012922D0 (en) | Novel compounds | |
GB201010508D0 (en) | Novel compounds | |
GB201010506D0 (en) | Novel compounds | |
GB201010509D0 (en) | Novel compounds | |
GB201010511D0 (en) | Novel compounds | |
GB201010512D0 (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
COOA | Change in applicant's name or ownership of the application |
Owner name: AUTIFONY THERAPEUTICS LIMITED Free format text: FORMER OWNER: GLAXO GROUP LIMITED |
|
AT | Applications terminated before publication under section 16(1) |